{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:52:21Z","timestamp":1791535941105,"version":"4.3.4"},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Poznan University of Medical Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We evaluated the prevalence of systemic sclerosis (SSc)-related autoantibodies and their clinical significance and compared the sensitivity of two line immunoblot assays on a prospective study group of 96 Polish SSc patients (ACR-EULAR 2013 criteria) whose sera were assessed by indirect immunofluorescence (HEp-2 and monkey liver) and line immunoblot assays: ANA Profile 3 and Systemic Sclerosis Profile by EUROIMMUN (L\u00fcbeck, Germany). Organ involvement was evaluated according to the EUSTAR Minimal Essential Data Set. The following autoantibodies\u2019 prevalence was found: Scl-70 (36%), Ro-52 (28%), CENP-B (22%), CENP-A (20%), PM-Scl-75 (20%), PM-Scl-100 (14%), fibrillarin (7%), Th\/To (7%), RNA polymerase III 11 kDa (5%), RNA polymerase III 155 kDa (3%), PDGFR (3%), NOR-90 (2%), and Ku (1%). Significant associations between the autoantibodies\u2019 presence and organ involvement were found: ATA (dcSSc &gt; lcSSc, less prevalent muscle weakness), Ro-52 (gangrene, DLCO &lt; 60), CENP-B and A (lcSSc &gt; dcSSc, normal CK), CENP-B (rarer digital ulcers and joint contractures), PM-Scl-100 and 75 (PM\/SSc overlap, CK increase, muscle weakness, muscle atrophy), PM-Scl-100 (dcSSc unlikely), PM-Scl-75 (lung fibrosis), fibrillarin (muscle atrophy, proteinuria, conduction blocks, palpitations), Th\/To (proteinuria, arthritis, muscle weakness, and rarer esophageal symptoms), RNA Polymerase III 11 kDa (arterial hypertension, renal crisis), RNA polymerase III 155 kDa (renal crisis), and PDGFR (dcSSc, tendon friction rubs). Additionally, the Systemic Sclerosis Profile was significantly more sensitive in detecting SSc-related autoantibodies than ANA Profile 3 (p = 0.002). In conclusion, individual autoantibodies associated with specific characteristics of SSc.<\/jats:p>","DOI":"10.3390\/jcm12020657","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:31:32Z","timestamp":1673843492000},"page":"657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Autoantibodies and Clinical Correlations in Polish Systemic Sclerosis Patients: A Cross-Sectional Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-9174","authenticated-orcid":false,"given":"Pawe\u0142","family":"\u017bebryk","sequence":"first","affiliation":[{"name":"Department of Medical Education, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8785-724X","authenticated-orcid":false,"given":"Piotr","family":"Przymusza\u0142a","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-2188","authenticated-orcid":false,"given":"Jan Krzysztof","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, 60-572 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Piorunek","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5282-1570","authenticated-orcid":false,"given":"Tatiana","family":"Mularek-Kubzdela","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Poznan University of Medical Sciences, 61-848 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Puszczewicz","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, 61-545 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"202","article-title":"Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","author":"Masi","year":"1980","journal-title":"Arthritis Rheum."},{"key":"ref_4","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9343(97)00023-5","article-title":"Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies","volume":"103","author":"Alter","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.cca.2010.01.037","article-title":"Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis","volume":"411","author":"Villalta","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jim.2012.03.001","article-title":"Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis","volume":"379","author":"Bonroy","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5114\/reum.2013.35767","article-title":"Antinuclear antibodies\u2014What to do with them?","volume":"51","author":"Puszczewicz","year":"2013","journal-title":"Reumatologia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12026-015-8710-9","article-title":"Detection of anti-U3-RNP\/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis","volume":"64","author":"Peterson","year":"2016","journal-title":"Immunol. Res."},{"key":"ref_11","first-page":"987","article-title":"Serological profile of patients with systemic sclerosis","volume":"68","author":"Wielosz","year":"2014","journal-title":"Adv. Hyg. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian Scleroderma Register: Autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: Correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/08916934.2011.592886","article-title":"Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients","volume":"44","year":"2011","journal-title":"Autoimmunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2622","article-title":"Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10067-019-04575-5","article-title":"Clinical and laboratory features of African-Brazilian patients with systemic sclerosis","volume":"39","author":"Mendes","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"key":"ref_21","first-page":"1081","article-title":"Predicting cardiopulmonary involvement in patients with systemic sclerosis: Complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies","volume":"56","author":"Markusse","year":"2017","journal-title":"Rheumatology"},{"key":"ref_22","first-page":"126","article-title":"Autoantibody profile in a cohort of Algerian patients with systemic sclerosis","volume":"78","author":"Tahiat","year":"2020","journal-title":"Ann. Biol. Clin."},{"key":"ref_23","first-page":"109","article-title":"To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?","volume":"36","author":"Boonstra","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.autrev.2009.02.018","article-title":"Anti-topoisomerase I autoantibodies in systemic sclerosis","volume":"8","author":"Czompoly","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/art.1780310309","article-title":"Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients","volume":"31","author":"Weiner","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_26","first-page":"33","article-title":"Serological and clinical profile of systemic sclerosis: Analysis in a cohort of patients from a single center in Northern Italy","volume":"153","author":"Priora","year":"2018","journal-title":"G. Ital. Derm. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","article-title":"Scleroderma lung disease","volume":"22","author":"Solomon","year":"2013","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"v59","DOI":"10.1093\/rheumatology\/ken271","article-title":"High-resolution computed tomography and scleroderma lung disease","volume":"47","author":"Wells","year":"2008","journal-title":"Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cca.2011.06.041","article-title":"Anti-centromere antibodies in a large cohort of systemic sclerosis patients: Comparison between immunofluorescence, CENP-A and CENP-B ELISA","volume":"412","author":"Mahler","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_30","first-page":"142","article-title":"Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis","volume":"27","author":"Russo","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_31","first-page":"1488","article-title":"Clinical and serological heterogeneity in patients with anticentromere antibodies","volume":"32","author":"Miyawaki","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/rheum.111133","article-title":"Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis","volume":"39","author":"Hudson","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/rheumatology\/37.1.15","article-title":"Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis","volume":"37","author":"Bunn","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.090677","article-title":"Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: A cross-sectional study","volume":"37","author":"Meyer","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","article-title":"Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay","volume":"48","author":"Satoh","year":"2009","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.reuma.2021.02.005","article-title":"Anti-RNA Polymerase III Antibodies in Systemic Sclerosis: Multicentric Study from Argentina","volume":"18","author":"Gargiulo","year":"2021","journal-title":"Reum. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/03009742.2011.610032","article-title":"Scleroderma renal crisis in a Swedish systemic sclerosis cohort: Survival, renal outcome, and RNA polymerase III antibodies as a risk factor","volume":"41","author":"Hesselstrand","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.100316","article-title":"Anti-Th\/To are common antinucleolar autoantibodies in Italian patients with scleroderma","volume":"37","author":"Ceribelli","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-Th\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3899\/jrheum.100754","article-title":"Antinuclear antibodies and clinical associations in a british cohort with limited cutaneous systemic sclerosis","volume":"38","author":"Gliddon","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5692\/clinicalneurol.cn-001509","article-title":"[A case of anti-Th\/To antibody-positive systemic sclerosis with muscle symptoms and interstitial pneumonia]","volume":"61","author":"Kikuchi","year":"2021","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/sji.12510","article-title":"The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis","volume":"85","author":"Tall","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3899\/jrheum.110071","article-title":"Anti-fibrillarin antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis","volume":"38","author":"Sharif","year":"2011","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"588753","DOI":"10.3389\/fimmu.2021.588753","article-title":"Correlation Between Skin and Affected Organs in 52 Sclerodermic Patients Followed in a Diseases Management Team: Development of a Risk Prediction Model of Organ-Specific Complications","volume":"12","author":"Cozzani","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_51","first-page":"189","article-title":"The prevalence and significance of anti-PM\/Scl antibodies in systemic sclerosis","volume":"28","author":"Wielosz","year":"2021","journal-title":"Ann. Agric. Env. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar3550","article-title":"International cohort study of 73 anti-Ku-positive patients: Association of p70\/p80 anti-Ku antibodies with joint\/bone features and differentiation of disease populations by using principal-components analysis","volume":"14","author":"Lakota","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: Clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: A European EUSTAR-initiated multi-centre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.semarthrit.2021.04.012","article-title":"The phenotype of myositis patients with anti-Ku autoantibodies","volume":"51","author":"Derfoul","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2021-eular.1477","article-title":"AB0427 Anti-nor90 autoantibodies: Favorable or unfavorable prognosis?","volume":"80","author":"Valero","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.31138\/mjr.29.3.120","article-title":"Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece","volume":"29","author":"Liaskos","year":"2018","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/rheumatology\/keab575","article-title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","volume":"61","author":"Yamashita","year":"2022","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_61","first-page":"1543","article-title":"Autoantibodies to NOR 90\/hUBF: Longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response","volume":"29","author":"Dagher","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-6-2","article-title":"Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis","volume":"6","author":"Parker","year":"2009","journal-title":"J. Autoimmune Dis."},{"key":"ref_64","first-page":"47","article-title":"Clinical and Autoantibody Associations in Antinuclear Antibody-Positive Systemic Sclerosis Lacking Prototypic Autoantibodies","volume":"29","author":"Kruzer","year":"2023","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/657\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:05:33Z","timestamp":1760119533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/2\/657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12020657"],"URL":"https:\/\/doi.org\/10.3390\/jcm12020657","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]}}}